Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRT-1 + MRT-2
- Development stage
- Preclinical
- Lead developer
- Oncodesign Precision Medicine
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MRT-1 + MRT-2 is a combination or pair of preclinical small molecule programs developed by Oncodesign Precision Medicine for the treatment of oncology. These assets are derived from Oncodesign's proprietary Nanocyclix platform, which focuses on the design of highly selective macrocyclic kinase inhibitors. While the specific biological targets for MRT-1 and MRT-2 remain undisclosed in public pipeline disclosures, they are part of the company's precision medicine portfolio aimed at addressing unmet needs in cancer therapy through targeted kinase modulation.
- Other names
- MRT 1 and 2MRT1 and 2MRT-1 and 2
Beyond the preview
Go deeper on MRT-1 + MRT-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRT-1 + MRT-2.